Glycerophosphodiester Phosphodiesterase Identified As Non-Reliable Serological Marker for Disease

Overview

Journal Microorganisms

Specialty Microbiology

Date 2020 Dec 1

PMID 33255178

Citations 6

Authors

Michael Reiter

Theresa Stelzer

Anna M Schotta

Mateusz Markowicz

Michael Leschnik

Anna Harsch

Edda Reiss

Richard E Kneusel

Hannes Stockinger

Gerold Stanek

Affiliations

Soon will be listed here.

Abstract

The relapsing fever group is an emerging tick-borne pathogen. Diagnosis of infection is currently mainly based on serological methods detecting antibodies against glycerophosphodiester phosphodiesterase (GlpQ). Here, we scrutinized the reliability of GlpQ as a diagnostic marker and compared the seroprevalence in different study populations and by applying various immunoblotting methods. Antibodies were detected in the sera of 7/53 hunters and in 1/11 sera of Lyme neuroborreliosis patients. Furthermore, 17/74 sera of persons with high concentrations of anti-Borrelia burgdorferi sensu lato (α-Bbsl) antibodies reacted strongly with GlpQ in immunoblots. The GlpQ seroprevalence was 7/50 in α-Bbsl negative persons. In healthy blood donors from commercial suppliers and from the Austrian Red Cross, seroprevalences were 5/14 and 10/35, respectively. Strikingly, two PCR-positive cases from Austria had negative GlpQ serology, indicating poor sensitivity. Finally, when we analyzed sera of dogs, we found α- GlpQ antibody seroprevalence in tick-free dogs ( = 10) and in tick-exposed dogs ( = 19) with 2/10 and 8/19, respectively. Thus, our results indicate that GlpQ-based serology holds neither specificity nor sensitivity.

Citing Articles

Tick-borne infections in children in North America.

Taylor-Salmon E, Shapiro E Curr Opin Pediatr. 2024; 36(2):156-163.

PMID: 38167816 PMC: 10932821. DOI: 10.1097/MOP.0000000000001326.

Human Infection in North America.

Burde J, Bloch E, Kelly J, Krause P Pathogens. 2023; 12(4).

PMID: 37111439 PMC: 10145171. DOI: 10.3390/pathogens12040553.

: A Comprehensive Review.

Cleveland D, Anderson C, Brissette C Pathogens. 2023; 12(2).

PMID: 36839539 PMC: 9967256. DOI: 10.3390/pathogens12020267.

Borrelia miyamotoi a neglected tick-borne relapsing fever spirochete in Thailand.

Takhampunya R, Longkunan A, Somchaimongkol S, Youngdech N, Chanarat N, Sakolvaree J PLoS Negl Trop Dis. 2023; 17(2):e0011159.

PMID: 36809255 PMC: 9983830. DOI: 10.1371/journal.pntd.0011159.

Development and Validation of a Protein Array for Detection of Antibodies against the Tick-Borne Pathogen Borrelia miyamotoi.

Hoornstra D, Stukolova O, Karan L, Sarksyan D, Kolyasnikova N, Markelov M Microbiol Spectr. 2022; 10(6):e0203622.

PMID: 36314925 PMC: 9769530. DOI: 10.1128/spectrum.02036-22.

References

Krause P, Fish D, Narasimhan S, Barbour A . Borrelia miyamotoi infection in nature and in humans. Clin Microbiol Infect. 2015; 21(7):631-9. PMC: 4470780. DOI: 10.1016/j.cmi.2015.02.006. View

Raffel S, Battisti J, Fischer R, Schwan T . Inactivation of genes for antigenic variation in the relapsing fever spirochete Borrelia hermsii reduces infectivity in mice and transmission by ticks. PLoS Pathog. 2014; 10(4):e1004056. PMC: 3974855. DOI: 10.1371/journal.ppat.1004056. View

Kalish R, McHugh G, Granquist J, Shea B, Ruthazer R, Steere A . Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis. 2001; 33(6):780-5. DOI: 10.1086/322669. View

Gugliotta J, Goethert H, Berardi V, Telford 3rd S . Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013; 368(3):240-5. PMC: 4018741. DOI: 10.1056/NEJMoa1209039. View

Schwan T, Battisti J, Porcella S, Raffel S, Schrumpf M, Fischer E . Glycerol-3-phosphate acquisition in spirochetes: distribution and biological activity of glycerophosphodiester phosphodiesterase (GlpQ) among Borrelia species. J Bacteriol. 2003; 185(4):1346-56. PMC: 142843. DOI: 10.1128/JB.185.4.1346-1356.2003. View

Schwan T, Schrumpf M, Hinnebusch B, Anderson Jr D, Konkel M . GlpQ: an antigen for serological discrimination between relapsing fever and Lyme borreliosis. J Clin Microbiol. 1996; 34(10):2483-92. PMC: 229300. DOI: 10.1128/jcm.34.10.2483-2492.1996. View

Molloy P, Telford 3rd S, Chowdri H, Lepore T, Gugliotta J, Weeks K . Borrelia miyamotoi Disease in the Northeastern United States: A Case Series. Ann Intern Med. 2015; 163(2):91-8. DOI: 10.7326/M15-0333. View

Szekeres S, Lugner J, Fingerle V, Margos G, Foldvari G . Prevalence of Borrelia miyamotoi and Borrelia burgdorferi sensu lato in questing ticks from a recreational coniferous forest of East Saxony, Germany. Ticks Tick Borne Dis. 2017; 8(6):922-927. DOI: 10.1016/j.ttbdis.2017.08.002. View

Porcella S, Raffel S, Schrumpf M, Schriefer M, Dennis D, Schwan T . Serodiagnosis of Louse-Borne relapsing fever with glycerophosphodiester phosphodiesterase (GlpQ) from Borrelia recurrentis. J Clin Microbiol. 2000; 38(10):3561-71. PMC: 87437. DOI: 10.1128/JCM.38.10.3561-3571.2000. View

10.

Hovius J, de Wever B, Sohne M, Brouwer M, Coumou J, Wagemakers A . A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet. 2013; 382(9892):658. PMC: 3987849. DOI: 10.1016/S0140-6736(13)61644-X. View

11.

Wormser G, Shapiro E, Fish D . Borrelia miyamotoi: An Emerging Tick-Borne Pathogen. Am J Med. 2018; 132(2):136-137. DOI: 10.1016/j.amjmed.2018.08.012. View

12.

Barbour A, Bunikis J, Travinsky B, Hoen A, Diuk-Wasser M, Fish D . Niche partitioning of Borrelia burgdorferi and Borrelia miyamotoi in the same tick vector and mammalian reservoir species. Am J Trop Med Hyg. 2009; 81(6):1120-31. PMC: 2841027. DOI: 10.4269/ajtmh.2009.09-0208. View

13.

Wagemakers A, Koetsveld J, Narasimhan S, Wickel M, DePonte K, Bleijlevens B . Variable Major Proteins as Targets for Specific Antibodies against Borrelia miyamotoi. J Immunol. 2016; 196(10):4185-95. PMC: 5008243. DOI: 10.4049/jimmunol.1600014. View

14.

Krause P, Narasimhan S, Wormser G, Barbour A, Platonov A, Brancato J . Borrelia miyamotoi sensu lato seroreactivity and seroprevalence in the northeastern United States. Emerg Infect Dis. 2014; 20(7):1183-90. PMC: 4073859. DOI: 10.3201/eid2007.131587. View

15.

Tobudic S, Burgmann H, Stanek G, Winkler S, Schotta A, Obermuller M . Human Borrelia miyamotoi Infection, Austria. Emerg Infect Dis. 2020; 26(9):2201-2204. PMC: 7454072. DOI: 10.3201/eid2609.191501. View

16.

Diaz P, Arnal J, Remesar S, Perez-Creo A, Venzal J, Vazquez-Lopez M . Molecular identification of Borrelia spirochetes in questing Ixodes ricinus from northwestern Spain. Parasit Vectors. 2017; 10(1):615. PMC: 5738910. DOI: 10.1186/s13071-017-2574-x. View

17.

Wagemakers A, Staarink P, Sprong H, Hovius J . Borrelia miyamotoi: a widespread tick-borne relapsing fever spirochete. Trends Parasitol. 2015; 31(6):260-9. DOI: 10.1016/j.pt.2015.03.008. View

18.

Platonov A, Karan L, Kolyasnikova N, Makhneva N, Toporkova M, Maleev V . Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011; 17(10):1816-23. PMC: 3310649. DOI: 10.3201/eid1710.101474. View

19.

Krause P, Narasimhan S, Wormser G, Rollend L, Fikrig E, Lepore T . Human Borrelia miyamotoi infection in the United States. N Engl J Med. 2013; 368(3):291-3. PMC: 3934646. DOI: 10.1056/NEJMc1215469. View

20.

Wagemakers A, Oei A, Fikrig M, Miellet W, Hovius J . The relapsing fever spirochete Borrelia miyamotoi is cultivable in a modified Kelly-Pettenkofer medium, and is resistant to human complement. Parasit Vectors. 2014; 7:418. PMC: 4261524. DOI: 10.1186/1756-3305-7-418. View